Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17467735 | 1.00 | PLA2G7 (0.47) | PLA2G7GRM2GRM5S1PR1S1PR5 | |
| SCHEMBL17460284 | 0.89 | PLA2G7 (0.45) | PLA2G7GRM2GRM5S1PR1S1PR5 | |
| SCHEMBL15901051 | 0.87 | PLA2G7 (0.51) | PLA2G7S1PR1GPR84 | |
| SCHEMBL15901050 | 0.87 | PLA2G7 (0.51) | PLA2G7S1PR1GPR84 | |
| SCHEMBL15901594 | 0.87 | PLA2G7 (0.50) | PLA2G7S1PR1GPR84 | |
| SCHEMBL15901592 | 0.87 | PLA2G7 (0.50) | PLA2G7S1PR1GPR84 | |
| SCHEMBL17467732 | 0.87 | PLA2G7 (0.41) | PLA2G7GRM2 | |
| SCHEMBL17460337 | 0.87 | PLA2G7 (0.41) | PLA2G7GRM2 | |
| SCHEMBL17460338 | 0.87 | PLA2G7 (0.41) | PLA2G7GRM2 | |
| SCHEMBL17467725 | 0.86 | PLA2G7 (0.51) | PLA2G7GRM2GRM5S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016012916-A1 | 1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |